Navigation Links
Medication appears well-tolerated, beneficial in Huntington's disease patients
Date:2/8/2010

A medication previously studied in patients with Alzheimer's disease (latrepirdine) appears well tolerated and may improve thinking, learning and memory skills among individuals with Huntington's disease, according to a report in the February issue of Archives of Neurology, one of the JAMA/Archives journals.

"Huntington's disease is a hereditary neurodegenerative disorder that affects movement, behavior and cognition and leads to death within 20 years of disease onset," the authors write as background information in the article. "Cognitive [thinking, learning and memory] impairment occurs early in the disease and deteriorates as Huntington's disease progresses, contributing to loss of ability to work and perform activities of daily living." The only approved therapy for Huntington's disease, tetrabenazine, treats only motor symptoms and does not alter the course of the disease or prevent cognitive decline.

Abnormalities in mitochondria, parts of cells that help convert food into energy, have been implicated in the development of Huntington's disease. The synthetic molecule latrepirdine stabilizes and improves mitochondrial function, and has been studied as a way to improve cognitive, behavioral and functional outcomes in patients with Alzheimer's disease. Karl Kieburtz, M.D., M.P.H., of the School of Medicine and Dentistry, University of Rochester, N.Y., and colleagues assessed the safety and tolerability of latrepirdine among 91 participants with mild to moderate Huntington's disease at enrollment (2007 to 2008).

For 90 days, 46 patients were randomly assigned to take 20 milligrams of latrepirdine three times daily and the other 45 took a matching placebo. The medication was well tolerated (87 percent of the patients given latrepirdine completed the study, compared with 82 percent in the control group) and adverse event rates were similar between the two groups (70 percent in the treatment group vs. 80 percent in the placebo group).

In addition, the treatment resulting in improved average scores on an evaluation measuring overall cognitive function. Scores of individuals in the placebo group remained steady over the study period.

"Taken together, our data suggest that latrepirdine, at a dosage of 20 milligrams three times daily, is well tolerated for 90 days in patients with Huntington's disease and may have a beneficial effect on cognition," the authors conclude. "Future studies of latrepirdine are planned to further evaluate the effect of latrepirdine on the cognitive and behavioral symptoms of Huntington's disease."


'/>"/>

Contact: Abena Foreman-Trice
abena@virginia.edu
434-243-2734
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. APA Comments on FDAs First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder
2. Manic phase of bipolar disorder benefits from breast cancer medication
3. AHRQ and FDA to Collaborate in Largest Study Ever of Possible Heart Risks with ADHD Medications
4. Mayo Clinic study indicates medication for ADHD may help student outcomes
5. Diet and medications may assist prevention of prostate cancer
6. Delmarva Foundation Implements Medication Therapy Management Program in Maryland and DC
7. Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors
8. Moses Taylor Hospital Automates Medication Reconciliation
9. Cautious Optimism for New Alzheimers Medications, Reports the Harvard Mental Health Letter
10. Patients cant recall their medications to tell doctors
11. Patient Empowerment -- Medication Error
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology: